Laboratory of Vivek Bhalla, MD- Stanford

Molecular Mechanisms of Kidney Disease, @StanfordNeph; Director, @Stanford_HTN; Director, @PreRenal_SU; @KidneyInCVD; @[email protected]

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

Thank you to @rmh199 @StanfordDeptMed for highlighting our work

[Stanford Department of Medicine @StanfordDeptMed]

Join nephrologist Dr. Vivek Bhalla (@BhallaResearch)
& Science Communicator Rebecca Handler (@rmh199) in the lab as he shares a story that began with a single patient’s case of early-onset kidney disease and led to a genetic discovery: https://t.co/khb914xwqE

#Nephrology

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@kidney_boy I’m so sorry

[World Congress of Nephrology @ISNWCN]

🎉 Great news! The WCN’27 abstract submission deadline has been extended!

📅 NEW DEADLINE: November 4, 23:59 CET.

Finalize your research and share it with the global kidney community at WCN’27 in Kuala Lumpur, April 1–4, 2027.

👏 Thank you to everyone who already submitted!

📢 Submit your abstract: https://t.co/NSspTnzRvf

#ISNWCN #WCN27 #WorldCongress #Congress #Nephrology #KidneyCare #KidneyHealth #MedicalResearch #GlobalHealth #ThisIsISN

[Yair Einhorn @yaireinhorn]

It seems the FDA has finally decided to cross the Rubicon and published a new and revolutionary regulatory framework which aims to expedite the regulatory approval process of new Gene Editing-based treatments - such as $BEAM Base Editing and $PRME Prime Editing.

These new proposed guidelines are the pinnacle of a regulatory process which began with a Cell and Gene Therapy Roundtable - held last year by FDA former commissioner @MartyMakary and the former director of the FDA’s Center for Biologics Evaluation and Research (CBER) @VPrasadMDMPH, in which researchers, industry leaders and scientists set together with FDA officials to bring new ideas to the table.

During this fascinating meeting Prof. @davidrliu from @Harvard & the @broadinstitute and most importantly the inventor of Base Editing and Prime Editing has made a closing statement which really caught my attention:

“It’s not only about treating 1,000 rare disease patients but about building a modular system that turns rare disease treatment into a national engine for therapeutic innovation and which will secure America’s leadership in Genetic medicine for the foreseeable future.”

It seems that finally Prof Liu’s call was answered!

[Dr Anastasia Mihailidou FAHA FCSANZ FESC @AnastasiaSMihai]

Very much looking forward to @AHAScience #ScientificSessions26 starting next week🙌

What a🌟program - Nobel laureate on clinical trials, OpenAI in the room, the first CKM guideline in practice, and so much more👏👏

Gratitude & excitement to co-Chair the🔥Results of the @American_Heart #Health #Equity #Research Network in the Community!

Congratulations @spjuraschek @ycommodore & all presenters & look forward to our session!

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@Nephro_Sparks @ASNKidney @adi_singh18 Thanks to @ASNKidney for sponsoring Kidney STARS. Had a great time along with our Campbell fellow Sharanya Ramesh introducing graduate students to KidneyWk. The future is bright for nephrology

[Rod Tan @RodTan07]

Come see what the Pittsburgh Center for Kidney Research can do to help your bench research - TH-INFO-11. I’m here to discuss! #kidneywk @pittkidneyctr

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@DGlaucomflecken receiving the ASN President’s Medal @ASNKidney

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

Guest appearance at ASN Kidney STARS! @DGlaucomflecken @ASNKidney #KidneyWeek

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@Nephro_Sparks Congrats, Matt

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek That’s a cool trial…

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek No

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek the large number of folks seen who have overt PA who were never screened and toiled away with med change after med change, and HTN complication after complication without definitive Rx

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek Thus, I agree that diagnostic thresholds should be tied to outcome. Also, the real concern you bring up of unnecessary surgery is less likely on this end of the spectrum. I do agree that we need more data. The push to screen and diagnose stems from …

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek I like the idea in principle, but I’m afraid we’d never get enrollment. A sham surgery is a huge lift for patients….

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek Lots of benefit of GLP-1RAs…no argument there. For me, it does come back to CVD / CKD risks of unopposed aldo….especially since we have targeted therapy….(medical or surgical)

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek @AHAScience likelihood of lateralization and likelihood of surgical cure. LI alone may not enough as we expand access, I agree.

[Laboratory of Vivek Bhalla, MD- Stanford @BhallaResearch]

@spjuraschek I prefer to do confirmatory testing, if for no other reason than to get repeat screening for free, but also we find interesting responses (@AHAScience poster FR557). the confirmatory tests aren’t “confirmatory”. I do feel we need to prioritize folks for AVS based on .. 1/2